When researchers or laboratory procurement teams evaluate a peptide supplier, a purity percentage by itself is not enough. The more useful question is whether the analytical record can be connected to a specific product, batch, test method, laboratory, and independently verifiable report. That distinction matters because several different documents can sit behind the broad label “COA,” yet those documents may answer very different questions.
CertaPeptides currently presents its analytical information through several connected layers: supplier batch specifications, a public COA Vault, independent third-party Janoshik Analytical reports for selected lots, and a batch-verification tool that accepts either a batch number or laboratory report code. The result is best understood as a documentation system rather than as a single purity claim. According to the current CertaPeptides COA and quality pages, supplier specifications cover the wider catalogue while selected lots receive independent third-party analytical testing, with the resulting reports published for verification.
Affiliate disclosure: This post contains an affiliate link; the publisher may earn a commission from qualifying purchases.
Research-use notice: CertaPeptides products discussed here are intended for controlled in-vitro/laboratory research by qualified researchers. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, food, supplements, cosmetics, or personal experimentation.
For qualified research purchasers who are already evaluating CertaPeptides, the CertaPeptides LOOT30 research catalogue can be accessed with promo code LOOT30 for up to 30% off. The commercial offer is secondary to the main subject of this guide: understanding exactly what the analytical records mean and how a procurement reader should interpret them.
The short answer: what should a CertaPeptides analytical record tell you?
A useful analytical record should help answer at least four separate questions.
First, what material is the document referring to? The product name, compound designation, batch identifier, or report code should allow a researcher to connect the record with an actual catalogue item or labelled lot.
Second, what analytical question was measured? HPLC purity, identity confirmation, and content quantification are related concepts, but they are not interchangeable. A high HPLC purity percentage does not automatically establish that the vial contains exactly the labelled mass, and a content measurement does not by itself replace an identity test.
Third, who produced the evidence? There is an important distinction between a supplier specification and an independent laboratory report. A specification describes the standard or expected characteristics of a product class or batch, whereas a third-party analytical report contains measurements produced by an external laboratory for a submitted sample.
Fourth, can the record be independently checked? CertaPeptides' current verification architecture allows a reader to enter a batch number or laboratory report code and, for published independently tested lots, follow the analytical record to the issuing laboratory's report.
Those four questions—material, measurement, source, and verification—are more informative than simply asking, “What is the purity?”
Why “COA” can mean more than one thing
Certificate of Analysis is one of the most commonly used phrases in laboratory procurement, but the label can hide important differences.
In its strictest practical sense, a COA is a document that associates analytical results with a particular material or lot. It may contain identifying information, analytical methods, acceptance criteria, measured results, dates, laboratory details, and authorization information. But suppliers do not necessarily structure their documents identically.
One supplier may call a class-level specification a COA. Another may reserve the term for a laboratory-generated batch report. Another may present both documents on the same product page.
That means procurement readers should read the fields rather than rely on the document title.
CertaPeptides currently distinguishes between supplier batch specifications and independent third-party reports. Its quality framework states that supplier specifications cover product lines while selected lots are independently tested through Janoshik Analytical, with new reports published as testing cycles complete. The company also states that it does not perform HPLC or mass-spectrometry testing in-house.
This distinction is useful because it prevents two different types of information from being treated as equivalent.
A supplier specification is mainly a statement of what a product is supposed to meet.
An independent analytical report is evidence of what an external laboratory measured in the submitted sample.
A strong procurement review uses both appropriately rather than treating one as a replacement for the other.
Supplier specification versus independent laboratory report
Imagine that a purchasing team is comparing two catalogue entries.
The first has a supplier specification stating that a product is expected to meet a defined identity and purity threshold.
The second has an independent laboratory report showing an actual measured purity result for a tested sample associated with that product or lot.
Those records answer different questions.
The specification asks:
What standard is this material expected to meet?
The independent test asks:
What did the laboratory measure in this particular submitted sample?
Neither question should be silently substituted for the other.
CertaPeptides currently describes this as a two-layer system. Its public documentation says supplier batch specifications apply across product lines while selected lots are independently tested and their reports made publicly available.
For procurement readers, that creates a useful interpretation rule:
Do not read a supplier specification as if it were a measured independent result, and do not assume that one independently tested lot establishes the analytical characteristics of every future lot.
The relevant record should always be matched to the material under consideration.
The importance of batch matching
A laboratory report becomes substantially more useful when the reader can connect it to a batch identifier.
Batch matching prevents a common documentation error: finding an impressive analytical report for the correct compound but the wrong production lot.
Suppose a procurement reader sees an HPLC result for Product X. The product name matches the material being purchased, but the report is associated with Batch A while the actual labelled material is Batch B.
That is not automatically evidence about Batch B.
A product name describes a class of material. A batch identifier narrows the record to a particular production or inventory lot.
The CertaPeptides verification page currently allows a user to enter a batch number printed on a vial or a laboratory report code. The system is designed to return either a supplier batch specification or, where available, the underlying independent third-party report.
For readers who want a more focused walkthrough of this matching process, the previously published article on CertaPeptides batch-code verification and matching the correct analytical record provides useful complementary context.
The practical lesson is simple: the compound name tells you what to look for; the batch code tells you whether you are looking at the correct record.
How CertaPeptides' current verification structure works
The current public-facing structure is built around several interconnected pages.
The COA Vault presents published analytical records and identifies whether an entry represents independent testing or a supplier specification.
The Verify tool accepts a batch number or report code.
The quality framework explains the distinction between supplier specifications and externally generated analytical results.
The independent verification page publishes third-party reports and provides links that allow users to compare the supplier-presented information with records associated with the testing laboratory.
The architecture matters because analytical transparency is stronger when records are connected.
A PDF sitting alone on a product page requires the reader to trust that the document is current and accurately associated with the material.
A record that can be searched by batch code, cross-referenced to a report identifier, and compared with an external laboratory record provides more opportunities for independent checking.
That still does not make any analytical system infallible. Sampling, handling, analytical method limitations, lot variation, and document-matching errors remain possible. But traceability makes those questions easier to investigate.
What HPLC purity actually tells a researcher
High-performance liquid chromatography, usually abbreviated HPLC, is widely used to separate components in a sample.
In peptide analysis, a purity figure often represents the relative chromatographic area associated with the principal detected component compared with other detected peaks under the conditions of that method.
That is valuable information, but the percentage needs to be interpreted correctly.
If a report states a high chromatographic purity, it generally indicates that the target-related primary peak dominates the chromatographic profile measured under those conditions.
It does not automatically mean:
- the vial contains exactly the labelled number of milligrams;
- every impurity type has been identified;
- microbiological sterility has been established;
- endotoxin has been measured;
- residual solvents have been excluded;
- elemental impurities have been excluded;
- stability through the entire intended storage period has been proven;
- every vial in a production run has been individually tested.
Those are different analytical questions requiring different methods or sampling strategies.
This is why procurement readers should resist reducing a multi-field report to one large percentage printed in bold.
CertaPeptides' current published records illustrate this distinction because some entries separately report chromatographic purity and measured content, while certain other entries are presented primarily as content-quantification records.
The most useful interpretation is therefore:
HPLC purity describes a chromatographic characteristic of the tested sample. It should not be silently converted into a universal statement about every other quality attribute.
Identity and mass spectrometry answer a different question
An analytical record may also contain mass-spectrometric evidence used to support molecular identity.
Conceptually, chromatography and mass spectrometry answer different questions.
Chromatography helps separate components and assess the relative composition of a sample under a defined method.
Mass spectrometry examines mass-to-charge information that can support confirmation that the detected material corresponds to the expected molecular species.
A useful way to think about the difference is:
HPLC asks, “How does this sample separate?”
Mass spectrometry asks, “Does the detected molecular mass support the expected identity?”
Neither question is identical to:
“How many milligrams of the target compound are actually present?”
That is why a procurement reader may encounter purity, identity, and content results on the same analytical record.
They are complementary measurements, not duplicate measurements.
CertaPeptides' current company information describes selected independent testing as involving HPLC and mass-spectrometry verification.
Content quantification: why purity percentage is not enough
One of the most important distinctions for non-specialist readers is the difference between purity and content.
Imagine a hypothetical sample whose target compound accounts for a very high percentage of detected chromatographic material.
That result says something important about relative purity.
But it does not necessarily tell you whether a vial labelled with a certain nominal content actually contains that exact mass of target material.
Content quantification addresses a different dimension: how much of the relevant material was measured.
That is why some analytical records present both a purity percentage and a measured-content value.
The current CertaPeptides COA archive includes examples where independently tested entries display an HPLC purity result alongside measured content and a percentage of the labelled quantity. Other entries, including some multi-component products, are represented as content-quantification records rather than a single straightforward purity percentage.
This distinction is especially important when comparing records across products.
A reader should not rank one record as “better” merely because it shows a larger percentage if the two percentages are measuring different characteristics.
Before comparing numbers, compare the measurement definitions.
A compact interpretation table
| Record field | Main question it helps answer | What it should not automatically be taken to prove |
|---|---|---|
| Product / compound name | What material is being described? | That the report matches the exact lot in hand |
| Batch / lot code | Which material lot is associated with the record? | That every unit was individually tested |
| HPLC purity | What relative chromatographic purity was measured? | Exact labelled content, sterility, endotoxin status, or every impurity class |
| Mass-spectrometry identity | Does molecular evidence support expected identity? | Exact quantitative content by itself |
| Content quantification | How much analyte was measured? | Every other quality attribute |
| Laboratory name | Who performed the testing? | That the document is authentic unless independently checked |
| Report / verification code | Can the external record be located? | That the physical item automatically belongs to that report without batch matching |
| Test date | When was the sample tested? | That all later lots have identical results |
The key is not to find the largest number in the document. The key is to understand what each number represents.
How to evaluate a Janoshik report without overreading it
Janoshik Analytical appears throughout CertaPeptides' current analytical documentation as an independent third-party laboratory used for selected published lots. CertaPeptides' own guide recommends comparing the report identifier and analytical fields against the laboratory-side record rather than relying solely on a supplier-displayed copy.
That verification process is valuable because document authenticity and analytical interpretation are separate issues.
A reader might first ask:
Is this really the laboratory's report?
Then:
Does this report correspond to the product and batch being evaluated?
Then:
What did the analytical methods actually establish?
Only after those steps should the reader begin interpreting specific percentages or measurements.
A laboratory report can be genuine but irrelevant to the lot being purchased.
A report can match the lot but contain a method that does not answer the procurement team's particular quality question.
A report can also provide strong evidence about certain attributes while saying nothing about others.
For this reason, independent verification should be treated as the beginning of interpretation, not the end.
Report code verification versus screenshot verification
A screenshot of a COA may be useful for quick communication, but it is a weaker verification mechanism than a report that can be independently located through a laboratory-side identifier.
Screenshots can be cropped.
Images can omit contextual fields.
Documents can become outdated.
Numbers can be copied into marketing graphics without preserving the complete analytical record.
A report code creates a reference point that can be checked against the issuing source.
CertaPeptides' current public guide explicitly recommends locating the report through the laboratory's own verification system and comparing fields rather than relying on the supplier copy alone.
The principle extends well beyond one supplier or one laboratory:
Whenever an independent testing laboratory provides a public verification mechanism, procurement teams should prefer laboratory-side verification over isolated screenshots.
What a procurement reader should compare between the supplier page and laboratory record
When both a supplier-displayed record and a laboratory-side report are available, the useful comparison is field-by-field.
Start with the compound or product identity.
Then compare the report identifier.
Check the test date.
Compare the reported chromatographic purity, if applicable.
Compare quantitative content measurements, if present.
Check the analytical methods or method descriptions.
Look for any mismatch between the supplier summary and the laboratory document.
A previously published guide on CertaPeptides COA red flags, Janoshik testing, and batch verification expands on warning signs that deserve attention during this comparison.
The most important concept is consistency.
Independent verification is useful precisely because it allows the reader to compare two representations of the same evidence.
If the laboratory record and supplier summary disagree materially, the discrepancy should be resolved before the analytical claim is relied upon for procurement decisions.
Analytical records should be read as evidence layers
Procurement teams often want a binary answer:
Is this product verified or not?
Analytical documentation rarely works so neatly.
Evidence usually exists in layers.
At the most general level, there may be a catalogue specification.
Then there may be a supplier batch record.
Then an independent sample may be submitted to an external laboratory.
That test may include one or more analytical techniques.
The resulting report may contain purity, identity, or content information.
The report may also be independently verifiable through a laboratory-side code.
Each additional layer strengthens a different part of the evidence chain.
This is why CertaPeptides' distinction between supplier specifications and independently published reports is more informative than simply attaching one “tested” label to the entire catalogue. Its quality framework explicitly describes these as separate tiers of documentation.
Readers who want a broader explanation of this documentation-first approach can also consult the prior article on how analytical records help researchers compare CertaPeptides products.
Why one tested lot should not be generalized to every lot
This is a foundational principle of batch documentation.
Independent testing of one submitted sample creates evidence about that tested sample and, depending on the documented relationship, the associated lot.
It does not logically prove that every previous or future batch has identical analytical characteristics.
Production inputs change.
Storage conditions differ.
Manufacturing runs may vary.
Sampling creates uncertainty.
Analytical methods themselves have defined performance characteristics and limitations.
That is why current batch matching matters more than a supplier's oldest or most impressive historical COA.
Historical reports can demonstrate that independent testing has occurred.
Current lot-specific records provide more directly relevant evidence for a current procurement decision.
CertaPeptides' current verification system attempts to address this by accepting batch numbers and linking available records to specific batch or laboratory identifiers.
How to read a supplier specification
A supplier specification should be approached as a requirements document.
Look for the product designation.
Check what attributes are specified.
Determine whether the values are targets, limits, ranges, or actual measurements.
Look for the relationship between the specification and the batch identifier.
Identify whether the document contains measured results or merely acceptance criteria.
This is especially important because phrases such as “purity specification” and “measured purity” can look similar while representing different evidence.
Suppose a specification states that a material is expected to meet a defined purity threshold.
That does not mean an external laboratory measured the exact vial in front of the reader and obtained that value.
The specification defines the expected quality criterion.
An analytical report records a measurement.
Keeping those two categories separate makes supplier comparisons considerably more rigorous.
How to read a third-party analytical report
For an independent report, the reading sequence changes slightly.
Start with the laboratory and report identifier.
Then identify the submitted material.
Check the test date.
Review the analytical method or methods.
Read the measured results in the context of those methods.
Determine whether the report contains purity, identity, content, or another type of analysis.
Finally, compare the report with the supplier's batch information.
This sequence matters because it prevents a number from being interpreted before the reader understands what was measured.
For non-specialists, the previously published explanation of CertaPeptides core COA and analytical fields can serve as a companion reference.
Analytical limitations are part of a good procurement review
A sophisticated analytical review does not only ask what a test establishes.
It also asks what the test does not establish.
This is especially important when marketing summaries compress several quality concepts into one line.
A chromatographic purity measurement is not the same thing as microbiological testing.
Mass confirmation is not the same thing as quantitative assay.
Testing a submitted sample is not the same thing as individually testing every vial.
A current COA is not necessarily evidence about unrelated future batches.
A high numerical result should therefore be treated as a result within a defined analytical context.
This is not a weakness unique to peptide analysis. It is how analytical evidence works generally: conclusions are bounded by the sample, method, calibration, detection capability, experimental conditions, and question being tested.
Good procurement therefore depends on precise language.
The difference between traceability and proof of every quality attribute
Traceability means being able to follow the relationship between material and records.
For example:
product → batch code → supplier specification → independent report → laboratory verification code.
That chain can be extremely valuable.
But traceability should not be confused with proof that every conceivable attribute has been tested.
A well-traced HPLC report is still an HPLC report.
If a procurement specification requires another analytical panel, the existence of chromatographic data does not remove that requirement.
CertaPeptides' quality page explicitly distinguishes its standard published analytical testing from other panels, noting that additional analyses such as endotoxin or microbiological-related testing are separate when present.
That is precisely the type of distinction procurement readers should look for.
Why report dates matter
Analytical reports exist in time.
The date helps establish when the sample was tested and assists readers in understanding whether a document is current, historical, or associated with a previous testing cycle.
A recent date is not automatically proof that a report applies to the currently offered batch.
Likewise, an older report is not automatically useless.
The relationship between the date and batch is what matters.
A strong review therefore combines three identifiers:
Product identity + batch identity + report date
If only the product name matches, the evidence chain is incomplete.
If the batch and report align, the record becomes more directly relevant.
Reading blend and multi-component records carefully
Multi-component materials deserve extra attention because a single headline percentage may not adequately describe the analytical question.
For a mixture containing multiple target compounds, researchers may need to know whether the analytical report distinguishes individual components, total content, identity for each component, or another combined measurement.
The current CertaPeptides COA archive contains records where multi-component entries are presented with component-specific or total content information rather than simply reducing the record to one purity percentage.
This is a useful reminder that the correct analytical presentation depends on the structure of the sample.
When comparing two products, make sure the displayed metric actually represents comparable measurements.
COA red flags procurement readers should recognize
Without turning analytical review into a forensic exercise, several warning signs deserve attention.
A report with no obvious relationship to the product being sold is weak evidence.
A report without a batch or report identifier is harder to trace.
An independent-lab logo without a laboratory-side verification path deserves closer inspection.
A purity percentage presented without explaining the method can be easily overinterpreted.
A very old report associated with an unidentified or different lot may have limited relevance to a current order.
A supplier summary that does not match the underlying laboratory record should not be ignored.
A document that treats purity, identity, and content as if they were synonymous suggests poor analytical communication.
The goal is not to assume misconduct. The goal is to determine whether the available documentation actually supports the claim being made.
A practical document-review sequence
A qualified procurement reader can keep the process compact:
- Identify the exact catalogue product being considered.
- Locate its batch or lot identifier when available.
- Open the associated supplier specification.
- Determine whether an independent laboratory report exists for that batch or relevant tested lot.
- Record the laboratory report identifier.
- Verify the report through the issuing laboratory when a verification mechanism is available.
- Compare product, batch, date, purity, identity, and quantitative fields.
- Identify what was not tested.
- Preserve the relevant records with the procurement file.
This should be treated as a documentation-review framework, not as a laboratory testing protocol.
Mid-article LOOT30 reminder for qualified research procurement
For research teams already considering the CertaPeptides catalogue, promo code LOOT30 is associated with up to 30% off.
That commercial offer should not replace documentation review. A lower acquisition cost does not make a weak analytical record stronger, and a strong analytical record should still be matched to the relevant batch before a purchase decision.
The useful order is therefore:
documentation first, commercial terms second.
Does a Janoshik report mean every CertaPeptides product is independently tested?
No.
CertaPeptides' current quality documentation distinguishes between supplier specifications that cover the catalogue and independent Janoshik testing performed on selected lots through rolling testing cycles.
This is an important distinction.
Saying “the supplier publishes Janoshik reports” is not the same as saying “every unit of every product has an individual Janoshik report.”
Readers should look at the specific product and batch record rather than generalizing from unrelated reports.
What does the CertaPeptides COA Vault currently provide?
The current COA Vault presents searchable analytical entries and distinguishes independently verified records from supplier specifications. Published independent entries can include fields such as product name, HPLC purity, measured content, report code, laboratory name, and test date depending on the type of test performed.
That makes the Vault most useful as a discovery layer.
The researcher can identify the relevant record, then move to the batch-verification or laboratory-verification step for deeper checking.
Is HPLC purity the same as peptide content?
No.
HPLC purity generally describes relative chromatographic composition under the test conditions.
Content quantification addresses how much target material is measured.
A sample can therefore have a high chromatographic purity result while its measured quantity differs from a nominal label amount.
That is why analytical records may display both values.
Does mass spectrometry replace HPLC?
No.
They provide different types of analytical information.
Mass spectrometry can support molecular identity.
HPLC can characterize chromatographic composition and relative purity.
A well-designed analytical assessment may use them together because identity and purity are different questions.
Can a supplier COA be independently verified?
Sometimes.
It depends on the origin and structure of the record.
When a report comes from an independent laboratory that operates a verification system, the laboratory's report identifier can provide an external reference.
CertaPeptides currently directs readers toward laboratory-side verification for its published independent reports rather than asking users to rely only on supplier-hosted copies.
What happens if a product only has a supplier specification?
Treat it as a supplier specification.
Do not silently upgrade it into an independent laboratory result.
The specification may still be useful because it defines the supplier's stated product requirements or batch criteria.
But the evidence category should remain clear.
CertaPeptides' present documentation explicitly distinguishes supplier-specification records from independent testing records.
What if the report code is valid but the batch does not match?
A valid report for a different batch is not the same as analytical evidence for the batch being reviewed.
The report may establish that the laboratory tested a sample associated with another lot, but procurement readers should not transfer those measurements to a new batch without an established documented relationship.
Batch matching is therefore an essential part of verification.
Should procurement teams save a copy of the COA?
For formal procurement and audit trails, retaining the material that supported the purchasing decision can be useful.
What should be retained depends on an organization's own quality system, but relevant records may include the product information, batch identifier, supplier specification, independent analytical report, verification reference, and date the information was checked.
Public webpages can change as suppliers update inventories and new reports become available.
An internal procurement record preserves the evidence that was actually reviewed at the time of the decision.
Is a high purity percentage enough to choose between suppliers?
Not by itself.
Supplier evaluation should consider whether the reported result is independently verifiable, whether it corresponds to the correct batch, what methods were used, what other analytical attributes matter to the research program, and how transparently the supplier distinguishes specifications from measured results.
A spectacular number without traceability may be less useful than a slightly less dramatic result backed by a clearly identified batch and independently verifiable report.
The objective is defensible evidence, not the largest marketing number.
Documentation quality is different from product claims
One of the most useful ways to evaluate research suppliers is to separate two questions.
Question one: What does the supplier claim about the product?
Question two: What documentation can a researcher independently inspect?
Analytical transparency does not mean accepting every supplier statement. It means making claims easier to examine.
CertaPeptides' current system includes publicly searchable records, batch verification, supplier specifications, and independent reports for selected lots. Those mechanisms give procurement readers multiple points where claims can be checked rather than requiring reliance on a single product-page statement.
The presence of that infrastructure does not remove the need for critical interpretation. It makes critical interpretation more practical.
Research procurement should remain evidence-led
A good research purchasing decision should be reproducible.
Another qualified reviewer should be able to look at the same product, batch, report, and verification information and understand why the documentation was considered sufficient—or insufficient—for the intended laboratory purpose.
That is a higher standard than simply seeing “99%+ purity” in a product description.
It requires knowing:
what was tested;
which sample was tested;
which lot the sample represents;
who performed the test;
which analytical method produced the result;
when the analysis occurred;
whether the report can be independently verified;
and which quality attributes were outside the scope of that analysis.
Once those questions become routine, COAs stop being marketing decorations and become what they should be: analytical records that support informed laboratory procurement.
Conclusion: read the evidence chain, not just the percentage
The most important lesson from the CertaPeptides analytical-record system is that purity, identity, content, specification, batch matching, and independent verification are separate concepts.
A supplier specification establishes an expected standard.
An HPLC result provides information about chromatographic purity.
Mass-spectrometric evidence can support molecular identity.
Content quantification addresses measured amount.
A batch identifier connects evidence to material.
A laboratory report code gives the researcher another path for checking authenticity.
Together, those fields create a much more useful procurement picture than a single headline number.
CertaPeptides' current public documentation provides both supplier-specification records and independently generated Janoshik reports for selected lots, with searchable COA and batch-verification tools connecting the records.
For researchers and procurement readers, the best practice is therefore straightforward: locate the product, match the batch, identify the analytical question, verify the independent record where available, and interpret each result only within the limits of the method that produced it.
CertaPeptides LOOT30: final research-procurement CTA
Qualified laboratory and research purchasers who have completed their documentation review can access the CertaPeptides research catalogue with LOOT30 and use promo code LOOT30 for up to 30% off.
The promotion should remain secondary to suitability, documentation, batch verification, institutional requirements, local law, and the needs of the research program.
Research-use reminder: CertaPeptides products are for controlled in-vitro/laboratory research by qualified researchers only. They are not for human or veterinary consumption, administration, treatment, diagnosis, clinical application, or personal experimentation.
Top comments (0)